2026-05-21T23:11:26Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/188162024-09-21T23:53:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Garcia de Lucas, Maria Dolores
author
Miramontes-González, Jose Pablo
author
Avilés-Bueno, Beatriz
author
Jiménez-Millán, Ana Isabel
author
Rivas-Ruiz, Francisco
author
Pérez-Belmonte, Luis M
2024-02-27T15:23:57Z
2024-02-27T15:23:57Z
2022-09-16
10.3389/fendo.2022.995646
1664-2392
Frontiers in endocrinology
http://hdl.handle.net/10668/20571
36187123
http://hdl.handle.net/20.500.12105/18816
To investigate the use of once-weekly semaglutide in a real population of people with type 2 diabetes mellitus (T2DM) in three Spanish hospitals. An observational, retrospective and multicenter clinical study was designed that included 166 participants with T2DM, distinguishing between a group naïve to GLP-1RA (n=72) and another switching from another GLP-1RA (n=94), all managed in the outpatient clinical setting. The primary endpoint was the change in HbA1c from baseline to the end of the study. The secondary endpoints included changes in body weight and the proportion of people with T2DM, achieving HbA1c 5%. After 24 months of follow-up, the reductions in HbA1c were -0.91 ± 0.7% (p In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM, without notable adverse effects, which supports real-world use.
eng
HbA1c
T2DM
body weight
once-weekly semaglutide
real-world use
Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
research article